Home Sectors Healthcare Buy or Sell: Eli Lilly And Company (NYSE: LLY)

Buy or Sell: Eli Lilly And Company (NYSE: LLY)


Eli Lilly And Company trades as part of the drug manufacturers industry and is part of the healthcare sector. The company CEO is David A. Ricks. Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.

Previous Intraday Trading Performance:

The LLY stock showed a previous change of 1.79% with an open at 117.73 and a close of 119.60. It reached an intraday high of 121.43 and a low of 117.45.

SeekingAlpha:  Lilly Q4: Looking At Low Verzenio Sales And The Loxo Oncology Acquisition


The stock has a market cap of $126.7b with 1.1b shares outstanding, of which the float is 1.1b shares. Trading volume reached 16,595,012 shares compared to its average volume of 5,372,666 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Eli Lilly And Company shares returned -0.47% and in the past 30 trading days it returned 5.94%. Over three months, it changed 11.92%. In one year it has changed 39.96% and within that year its 52-week high was 121.84 and its 52-week low was 74.51. LLY stock is 60.52% above its 52 Week Low.

Our calculations show a 200 day moving average of 101.13 and a 50 day moving average of 115.32. Currently LLY stock is trading 18.26% above its 200 day moving average.

PR Newswire:  Lilly to Participate in Guggenheim Healthcare Talks Idea Forum


The last annual fiscal EPS for the company was reported at 5.56 that ended on 31st of December 2018. Based on 4 analyst estimates, the consensus EPS for the next quarter is 1.36. The TTM EPS is 5.56, which comes to a TTM PE of 21.51.

The following are the last four quarter reported earnings per share:
12-31-2018:  1.33
09-30-2018:  1.39
06-30-2018:  1.50
03-31-2018:  1.34

The dividend per share is currently 2.58, which is a dividend yield of 2.16%. Also, the payout ratio is 46.40%, therefore the dividend is safe according to our calculations.

Base on our calculations, the intrinsic value per share is 107.78, which means it may be overvalued by -10.97%

Indicators to Watch:

Based on the latest filings, there is 0.40% of insider ownership and 109.20% of institutional ownership. Short-interest is 30,267,873, which is 2.86% of shares outstanding. The short-interest ratio or days-to-cover ratio is 5.58. This stock has some short interest, but it may be normal and no cause for concern if long the position.

The current calculated beta is 0.32

CNBC:  Stocks making the biggest moves premarket: Hasbro, Coty, Expedia, Verizon & more

Fundamental Indicators:

Based on last reported financials, the company’s return on assets is 7.19%, profit margin is 13.16%, price-to-sales is 5.07 and price-to-book is 9.69.

Company Scores:

All scores are out of six:
 0  :Valuation Score
 2  :Past Performance Score
 4  :Financial Strength Score
 3  :Future Growth Score
 5  :Dividend Score
 2  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.